6 completed, 2 recruiting, 2 terminated, 2 unknown. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 6, Recruiting 2, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
Follow CBD: new trials by email Literature Review of CBD trials Research Report on CBD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjunctive Cannabidiol for Recovery From Opioid Study Cannabidiol, Placebo - Opioid Use Disorder (OUD) | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 450 | 2025-06-13 | 2026-10-01 |
| Cannabidiol for Bipolar Depression (CBD-BD) Cannabidiol, Placebo - Bipolar Disorder | Phase 3 | Recruiting | University of British Columbia | 360 | 2023-10-15 | 2025-04-23 |
| Topical CBD for Musculoskeletal Pain CBD, Control - Musculoskeletal Pain | Phase 2 / Phase 3 | Withdrawn | University of Virginia | 2022-01-01 | 2024-02-28 | |
| CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms Cannabidiol, PLACEBO - SARS-CoV2 | Phase 2 / Phase 3 | Unknown | University of Sao Paulo | 100 | 2020-07-06 | 2021-09-28 |
| A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome GWP42003-P - Rett Syndrome, RTT | Phase 3 | Terminated | Jazz Pharmaceuticals | 21 | 2020-02-28 | 2022-08-08 |
| Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome GWP42003-P, Placebo - Rett Syndrome, RTT | Phase 3 | Terminated | Jazz Pharmaceuticals | 29 | 2019-07-29 | 2022-09-02 |
| A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy Cannabidiol, Placebo - Epilepsy | Phase 3 | Unknown | Antonio Waldo Zuardi | 126 | 2019-01-09 | 2023-11-29 |
| Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) GWP42003-P - Infantile Spasms | Phase 3 | Completed | Jazz Pharmaceuticals | 9 | 2017-05-12 | 2022-09-02 |
| Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) GWP42003-P - Infantile Spasms | Phase 3 | Completed | Jazz Pharmaceuticals | 9 | 2017-04-24 | 2022-09-02 |
| An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) GWP42003-P - Tuberous Sclerosis Complex, Seizures | Phase 3 | Completed | Jazz Pharmaceuticals | 199 | 2016-08-31 | 2022-07-14 |
| A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) GWP42003-P, Placebo - Tuberous Sclerosis Complex, Seizures | Phase 3 | Completed | Jazz Pharmaceuticals | 224 | 2016-04-06 | 2022-09-28 |
| An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes GWP42003-P - Epilepsy, Dravet Syndrome | Phase 3 | Completed | GW Research Ltd | 681 | 2015-06-11 | 2022-02-03 |
| GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome GWP42003-P, Placebo Control - Epilepsy, Dravet Syndrome | Phase 3 | Completed | Jazz Pharmaceuticals | 199 | 2015-04-13 | 2022-09-28 |
Epilepsy (3) · Epilepsies, Myoclonic (2) · Rett Syndrome (2) · Seizures (2) · Spasms, Infantile (2) · Tuberous Sclerosis (2) · Bipolar Disorder (1) · Depression (1) · Lennox Gastaut Syndrome (1) · Mood Disorders (1) · Musculoskeletal Pain (1) · Opioid-Related Disorders (1)
Jazz Pharmaceuticals (7) · Antonio Waldo Zuardi (1) · GW Research Ltd (1) · Icahn School of Medicine at Mount Sinai (1) · University of British Columbia (1) · University of Sao Paulo (1) · University of Virginia (1)
United States (9) · Poland (4) · Spain (4) · Australia (3) · United Kingdom (3) · Brazil (2) · Canada (2) · Italy (2) · Netherlands (2) · Israel (1)
Brent DeGeorge, MD, PhD (1) · Lakshmi N Yatham, MBBS, MRCPsy (1) · Yasmin Hurd, PhD (1)
PMID 34957550, PMID 32119035, PMID 33346789, PMID 34265088, PMID 34287833, PMID 34406656, PMID 34619044, PMID 35175622, PMID 38441854
2015 (4), 2014 (2), 2018 (1), 2019 (1), UH3DA050323 (1)